Timing of Smoking Intervention in Alcohol Treatment (Nicotine Patch)

This study has been completed.

First Received on November 2, 1999. Last Updated on February 10, 2011 History of Changes

Sponsor:	Minneapolis Veterans Affairs Medical Center
Collaborator:	National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information provided by:	Minneapolis Veterans Affairs Medical Center
ClinicalTrials.gov Identifier:	NCT00000444

Purpose

This study will attempt to determine the best time to begin a smoking cessation program in individuals who undergo intensive treatment for alcohol dependence. The goal of this trial is to determine whether a smoking cessation program is more effective if it occurs at the same time as or after treatment for alcohol dependence. The study also will attempt to determine the effect of smoking cessation programs on the outcome of treatment for alcohol dependence.

Condition	Intervention	Phase
Alcoholism Smoking	Drug: nicotine replacement patch	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Masking: Open Label Primary Purpose: Treatment
Official Title:	Timing of Smoking Intervention in Alcohol Treatment

Resource links provided by NLM:

MedlinePlus related topics: Alcoholism Quitting Smoking Smoking

Drug Information available for: Nicotine tartrate Nicotine polacrilex

U.S. FDA Resources

Further study details as provided by Minneapolis Veterans Affairs Medical Center:

Estimated Enrollment:	500
Study Start Date:	September 1997
Study Completion Date:	January 2004
Primary Completion Date:	January 2004 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	21 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Meets criteria for alcohol use disorder and other drug dependence.
Complete first week of alcohol treatment program.
Current cigarette smoker (more than 5 cigarettes/day, smoking more than 1 year).

Exclusion Criteria:

Lifetime diagnosis of an excluding psychiatric disorder: bipolar disorder, schizophrenia or other psychotic disorder, panic disorder with or without agoraphobia, obsessive-compulsive disorder, generalized anxiety disorder, eating disorder, post- traumatic stress disorder, antisocial personality disorder, or borderline personality disorder.
Unable to participate in protocol due to functional deficits or severe depression.
Suicidal or homicidal ideation.
Current use of disulfiram (Antabuse) or naltrexone (Revia).
Current use of pipes, cigars, or smokeless tobacco and unwillingness to stop.
Lives more than 100 miles from alcohol treatment facility.
No telephone.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000444

Locations

United States, Minnesota
General Internal Medicine, VA Medical Center
Minneapolis, Minnesota, United States, 55417

Sponsors and Collaborators

Minneapolis Veterans Affairs Medical Center

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00000444 History of Changes
Other Study ID Numbers:	NIAAAJOS11124, R01AA011124
Study First Received:	November 2, 1999
Last Updated:	February 10, 2011
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Alcoholism
Smoking
Alcohol-Related Disorders
Substance-Related Disorders
Mental Disorders
Habits
Nicotine
Nicotine polacrilex
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents

Physiological Effects of Drugs
Pharmacologic Actions
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Central Nervous System Stimulants
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on February 12, 2012